Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
H.R.1319, American Rescue Plan Act FTC Reauthorization Act of 2021 (Not introduced) Review of Administration COVID policies
American Rescue Plan Act of 2021
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
H.R.1319, American Rescue Plan Act Issues related to pricing, reimbursement, and manufacturing of pharmaceutical products Review of Administration telehealth policies
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AVANOS MEDICAL, INC. (FKA HALYARD HEALTH, INC.) via POLSINELLI PC
2026 · third_quarter · Q3
-Proposed Medicare coverage policies pertaining to pain management therapies -Renewal of the No Pain Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Source: Senate LDA
| ROCKWELL MEDICAL TECHNOLOGIES, INC. |
| 14 |
| 2015–2018 |
| TEVA PHARMACEUTICALS USA INC | 10 | 2019–2021 |
| UNIVERSITY OF KANSAS HOSPITAL AUTHORITY | 10 | 2015–2017 |
| CEMPRA PHARMACEUTICALS | 9 | 2014–2016 |
| HEARING INDUSTRIES ASSOCIATION | 9 | 2019–2021 |
| QUEST DIAGNOSTICS | 8 | 2016–2017 |
| AMERICAN GLAUCOMA SOCIETY | 7 | 2021–2026 |
| HAPPIEST BABY, INC. | 7 | 2020–2021 |
| ORGANOVO HOLDINGS, INC. FKA: ORGANOVO, INC. | 7 | 2014–2016 |
| SONEX HEALTH, INC. | 7 | 2025–2026 |
| GT MEDICAL TECHNOLOGIES, INC. | 6 | 2020–2021 |
| ICAD, INC. | 6 | 2020–2021 |
| NATIONAL BOARD FOR HEALTH AND WELLNESS COACHING | 6 | 2025–2026 |
| XSTRAHL INC | 6 | 2025–2026 |
| AMERICANS FOR ORGAN TRANSPLANT ACCESS | 5 | 2017 |
| AMERITOX | 5 | 2015–2016 |
| RIDDELL SPORTS, INC. | 4 | 2020–2021 |
| THERAGENICS | 4 | 2010–2011 |
| CERAPEDICS, INC. | 3 | 2025 |
| DIGITAL DIAGNOSTICS INC (FKA: IDX TECHNOLOGIES INC | 1 | 2019 |
American Rescue Plan Act of 2021
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
H.R.1319, American Rescue Plan Act Issues related to pricing, reimbursement, and manufacturing of pharmaceutical products Review of Administration telehealth policies
Issues related to the implementation of the Drug Quality & Security Act (Public Law 113-54) HR 7518 The Safer Compounding in Hospitals Act
Issues related to the implementation of the Drug Quality & Security Act (Public Law 113-54) HR 7518 The Safer Compounding in Hospitals Act
Consolidated Appropriations Act, 2021
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 133, FY2021 Omnibus and COVID Relief and Response Act Review of Administration drug pricing and telehealth policies
Consolidated Appropriations Act, 2021
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 133, FY2021 Omnibus and COVID Relief and Response Act Review of Administration drug pricing and telehealth policies
H.R. 280, Concussion Awareness and Education Act FTC Reauthorization Act of 2020 (Not introduced) H.R. 133, FY2021 Omnibus and COVID Relief and Response Act
Concussion Awareness and Education Act of 2019
Client: RIDDELL SPORTS, INC. · Firm: POLSINELLI PC
H.R. 280, Concussion Awareness and Education Act FTC Reauthorization Act of 2020 (Not introduced) H.R. 133, FY2021 Omnibus and COVID Relief and Response Act
Concussion Awareness and Education Act of 2019
Client: RIDDELL SPORTS, INC. · Firm: POLSINELLI PC
H.R. 280, Concussion Awareness and Education Act FTC Reauthorization Act of 2020 (Not introduced) Coronavirus stimulus legislation H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act
Elijah E. Cummings Lower Drug Costs Now Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing policies
Elijah E. Cummings Lower Drug Costs Now Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, Families First Coronavirus Response Act H.R. 748, CARES Act Review of Administration drug pricing policies
Elijah E. Cummings Lower Drug Costs Now Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 133, FY2021 Omnibus and COVID Relief and Response Act Review of Administration drug pricing and telehealth policies
Elijah E. Cummings Lower Drug Costs Now Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing and telehealth policies H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act
Elijah E. Cummings Lower Drug Costs Now Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, Families First Coronavirus Response Act H.R. 748, CARES Act Review of Administration drug pricing policies
Elijah E. Cummings Lower Drug Costs Now Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing policies
Elijah E. Cummings Lower Drug Costs Now Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing and telehealth policies H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act
Elijah E. Cummings Lower Drug Costs Now Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 133, FY2021 Omnibus and COVID Relief and Response Act Review of Administration drug pricing and telehealth policies
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, Families First Coronavirus Response Act H.R. 748, CARES Act Review of Administration drug pricing policies
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, Families First Coronavirus Response Act H.R. 748, CARES Act Review of Administration drug pricing policies
Families First Coronavirus Response Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, Families First Coronavirus Response Act H.R. 748, CARES Act Review of Administration drug pricing policies
Families First Coronavirus Response Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, Families First Coronavirus Response Act H.R. 748, CARES Act Review of Administration drug pricing policies
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, Families First Coronavirus Response Act H.R. 748, CARES Act Review of Administration drug pricing policies
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, Families First Coronavirus Response Act H.R. 748, CARES Act Review of Administration drug pricing policies
Issues related to the implementation of the Drug Quality & Security Act (Public Law 113-54) HR 7518 The Safer Compounding in Hospitals Act
Continuing Appropriations Act, 2021 and Other Extensions Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing and telehealth policies H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act
Continuing Appropriations Act, 2021 and Other Extensions Act
Client: RIDDELL SPORTS, INC. · Firm: POLSINELLI PC
H.R. 280, Concussion Awareness and Education Act FTC Reauthorization Act of 2020 (Not introduced) Coronavirus stimulus legislation H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act
Continuing Appropriations Act, 2021 and Other Extensions Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing and telehealth policies H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, Families First Coronavirus Response Act H.R. 748, CARES Act Review of Administration drug pricing policies
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing policies
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing policies
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 133, FY2021 Omnibus and COVID Relief and Response Act Review of Administration drug pricing and telehealth policies
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing and telehealth policies H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing and telehealth policies H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, Families First Coronavirus Response Act H.R. 748, CARES Act Review of Administration drug pricing policies
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 133, FY2021 Omnibus and COVID Relief and Response Act Review of Administration drug pricing and telehealth policies
Prescription Drug Pricing Reduction Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 133, FY2021 Omnibus and COVID Relief and Response Act Review of Administration drug pricing and telehealth policies
Prescription Drug Pricing Reduction Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, Families First Coronavirus Response Act H.R. 748, CARES Act Review of Administration drug pricing policies
Prescription Drug Pricing Reduction Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing and telehealth policies H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act
Prescription Drug Pricing Reduction Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing policies
Prescription Drug Pricing Reduction Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, Families First Coronavirus Response Act H.R. 748, CARES Act Review of Administration drug pricing policies
Prescription Drug Pricing Reduction Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing and telehealth policies H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act
Prescription Drug Pricing Reduction Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing policies
Prescription Drug Pricing Reduction Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 133, FY2021 Omnibus and COVID Relief and Response Act Review of Administration drug pricing and telehealth policies
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
SUPPORT for Patients and Communities Act
Client: AVANOS MEDICAL, INC. (FKA HALYARD HEALTH, INC.) · Firm: POLSINELLI PC
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
SUPPORT for Patients and Communities Act
Client: AVANOS MEDICAL, INC. (FKA HALYARD HEALTH, INC.) · Firm: POLSINELLI PC
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
SUPPORT for Patients and Communities Act
Client: AVANOS MEDICAL, INC. (FKA HALYARD HEALTH, INC.) · Firm: POLSINELLI PC
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
Protecting Consumer Access to Generic Drugs Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
Protecting Consumer Access to Generic Drugs Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
Orange Book Transparency Act of 2020
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
Orange Book Transparency Act of 2020
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
Further Extension of Continuing Appropriations Act, 2021
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
Further Extension of Continuing Appropriations Act, 2021
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
Further Consolidated Appropriations Act, 2020
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.1865, FY2020 Further Consolidated Appropriations Act Administration review of drug pricing policies
Further Consolidated Appropriations Act, 2020
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.1865, FY2020 Further Consolidated Appropriations Act Administration review of drug pricing policies
Issues pertaining to the medical device excise tax [Further Consolidated Appropriations Act 2020 (HR 1865, Sec 501)]
Protect Medical Innovation Act of 2019
Client: AVANOS MEDICAL, INC. (FKA HALYARD HEALTH, INC.) · Firm: POLSINELLI PC
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act * Medical Device Tax Repeal Legislation * S 692/HR 2207 Protect Medical Innovation Act of 2019
Protect Medical Innovation Act of 2019
Client: AVANOS MEDICAL, INC. (FKA HALYARD HEALTH, INC.) · Firm: POLSINELLI PC
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act * Medical Device Tax Repeal Legislation * S 692/HR 2207 Protect Medical Innovation Act of 2019 S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
More Efficient Tools to Realize Information for Consumers Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2296, METRIC Act Administration review of drug pricing policies
More Efficient Tools to Realize Information for Consumers Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2296, METRIC Act Administration review of drug pricing policies
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
Preserve Access to Affordable Generics and Biosimilars Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.1865, FY2020 Further Consolidated Appropriations Act Administration review of drug pricing policies
Preserve Access to Affordable Generics and Biosimilars Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2296, METRIC Act Administration review of drug pricing policies
Preserve Access to Affordable Generics and Biosimilars Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
Preserve Access to Affordable Generics and Biosimilars Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
Preserve Access to Affordable Generics and Biosimilars Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2296, METRIC Act Administration review of drug pricing policies
Preserve Access to Affordable Generics and Biosimilars Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.1865, FY2020 Further Consolidated Appropriations Act Administration review of drug pricing policies
Prescription Pricing for the People Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
Prescription Pricing for the People Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
Elijah E. Cummings Lower Drug Costs Now Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.1865, FY2020 Further Consolidated Appropriations Act Administration review of drug pricing policies
Elijah E. Cummings Lower Drug Costs Now Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2296, METRIC Act Administration review of drug pricing policies
Elijah E. Cummings Lower Drug Costs Now Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2296, METRIC Act Administration review of drug pricing policies
Elijah E. Cummings Lower Drug Costs Now Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.1865, FY2020 Further Consolidated Appropriations Act Administration review of drug pricing policies
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act * Medical Device Tax Repeal Legislation * S 692/HR 2207 Protect Medical Innovation Act of 2019 S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
Tribal Health Care Protection Fund Act
Client: AMERICAN SOCIETY OF CLINICAL ONCOLOGY · Firm: POLSINELLI PC
Issues pertaining to the federal governments regulation and coverage of cancer care and treatments (Covering Life-saving Investigations Needed in Cancer and Other Life-threatening Conditions through Timely use of Resources for Easy and Affordable Treatment from Medicaid for Enrollees in Need Today Act - H.R. 6836)
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
Prescription Pricing for the People Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
Prescription Pricing for the People Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
Affordable Prescriptions for Patients Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
Affordable Prescriptions for Patients Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.1865, FY2020 Further Consolidated Appropriations Act Administration review of drug pricing policies
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.1865, FY2020 Further Consolidated Appropriations Act Administration review of drug pricing policies
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2296, METRIC Act Administration review of drug pricing policies
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2296, METRIC Act Administration review of drug pricing policies
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies
Prescription Drug Pricing Reduction Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2296, METRIC Act Administration review of drug pricing policies
Prescription Drug Pricing Reduction Act of 2019
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: POLSINELLI PC
S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.1865, FY2020 Further Consolidated Appropriations Act Administration review of drug pricing policies
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SONEX HEALTH, INC. via POLSINELLI PC
2026 · third_quarter · Q3
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
NATIONAL BOARD FOR HEALTH AND WELLNESS COACHING via POLSINELLI PC
2026 · third_quarter · Q3
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN GLAUCOMA SOCIETY via POLSINELLI PC
2026 · third_quarter · Q3
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PROCEPT BIOROBOTICS via POLSINELLI PC
2026 · third_quarter · Q3
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SONEX HEALTH, INC. via POLSINELLI PC
2026 · second_quarter · Q2
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
NATIONAL BOARD FOR HEALTH AND WELLNESS COACHING via POLSINELLI PC
2026 · second_quarter · Q2
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN GLAUCOMA SOCIETY via POLSINELLI PC
2026 · second_quarter · Q2
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PROCEPT BIOROBOTICS via POLSINELLI PC
2026 · second_quarter · Q2
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AVANOS MEDICAL, INC. (FKA HALYARD HEALTH, INC.) via POLSINELLI PC
2026 · second_quarter · 2A
Proposed Medicare coverage policies pertaining to pain management therapies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVANOS MEDICAL, INC. (FKA HALYARD HEALTH, INC.) via POLSINELLI PC
2026 · second_quarter · Q2
Proposed Medicare coverage policies pertaining to pain management therapies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SONEX HEALTH, INC. via POLSINELLI PC
2026 · first_quarter · Q1
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
NATIONAL BOARD FOR HEALTH AND WELLNESS COACHING via POLSINELLI PC
2026 · first_quarter · Q1
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN GLAUCOMA SOCIETY via POLSINELLI PC
2026 · first_quarter · Q1
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PROCEPT BIOROBOTICS via POLSINELLI PC
2026 · first_quarter · Q1
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Q4
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SONEX HEALTH, INC. via POLSINELLI PC
2025 · fourth_quarter · Q4
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
NATIONAL BOARD FOR HEALTH AND WELLNESS COACHING via POLSINELLI PC
2025 · fourth_quarter · Q4
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN GLAUCOMA SOCIETY via POLSINELLI PC
2025 · fourth_quarter · Q4
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PROCEPT BIOROBOTICS via POLSINELLI PC
2025 · fourth_quarter · Q4
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PROCEPT BIOROBOTICS via POLSINELLI PC
2025 · third_quarter · 3A
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Q3
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · RR
Issues related to the coverage, coding, and reimbursement of products and services under Medicare
SONEX HEALTH, INC. via POLSINELLI PC
2025 · third_quarter · Q3
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
CERAPEDICS, INC. via POLSINELLI PC
2025 · third_quarter · Q3
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES
NATIONAL BOARD FOR HEALTH AND WELLNESS COACHING via POLSINELLI PC
2025 · third_quarter · Q3
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN GLAUCOMA SOCIETY via POLSINELLI PC
2025 · third_quarter · Q3
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SONEX HEALTH, INC. via POLSINELLI PC
2025 · second_quarter · Q2
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
CERAPEDICS, INC. via POLSINELLI PC
2025 · second_quarter · Q2
Issues related to the coverage, coding and reimbursement of products and services under Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES
PROCEPT BIOROBOTICS via POLSINELLI PC
2025 · third_quarter · RA
Issues related to the coverage, coding and reimbursement of products and services under Medicare
AMERICAN GLAUCOMA SOCIETY via POLSINELLI PC
2025 · third_quarter · RA
Issues related to the coverage, coding and reimbursement of products and services under Medicare
NATIONAL BOARD FOR HEALTH AND WELLNESS COACHING via POLSINELLI PC
2025 · third_quarter · RR
Issues related to the coverage, coding and reimbursement of products and services under Medicare
SONEX HEALTH, INC. via POLSINELLI PC
2025 · second_quarter · RR
Issues related to the coverage, coding and reimbursement of products and services under Medicare
CERAPEDICS, INC. via POLSINELLI PC
2025 · second_quarter · RR
Issues related to the coverage, coding and reimbursement of products and services under Medicare
2021 · third_quarter · 3T
Issues related to the coverage and reimbursement of cancer therapies and diagnostic products.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HAPPIEST BABY, INC. via POLSINELLI PC
2021 · third_quarter · 3T
Issues pertaining to the use of products by health care providers and consumers
Issues pertaining to the use of products by health care providers and consumers
Issues pertaining to the use of products by health care providers and consumers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROCEPT BIOROBOTICS via POLSINELLI PC
2021 · third_quarter · 3T
Issues pertaining to Medicare coverage of medical devices
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · third_quarter · 3T
Issues pertaining to patient access to cancer therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN GLAUCOMA SOCIETY via POLSINELLI PC
2021 · third_quarter · RR
Issues related to CMS and congressional outreach.
2021 · second_quarter · Q2
Issues related to the coverage and reimbursement of cancer therapies and diagnostic products.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HAPPIEST BABY, INC. via POLSINELLI PC
2021 · second_quarter · Q2
Issues pertaining to the use of products by health care providers and consumers
Issues pertaining to the use of products by health care providers and consumers
Issues pertaining to the use of products by health care providers and consumers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROCEPT BIOROBOTICS via POLSINELLI PC
2021 · second_quarter · Q2
Issues pertaining to Medicare coverage of medical devices
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · second_quarter · Q2
Issues pertaining to patient access to cancer therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · 2T
Issues related to patient safety and quality
Issues related to the implementation of the Drug Quality & Security Act (Public Law 113-54) HR 7518 The Safer Compounding in Hospitals Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Q2
Issues related to increased access to radiation oncology therapies
- Issues related to oncology treatment products and services - Issues pertaining to the cybersecurity of critical infrastructure and connected devices
Issues related to radiation oncology treatment Issues pertaining to the Radiation Oncology Alternative Payment Model
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TEVA PHARMACEUTICALS USA, INC. via POLSINELLI PC
2021 · second_quarter · Q2
Issues related to pricing, reimbursement, and manufacturing of pharmaceutical products Review of Administration telehealth policies
Issues related to pricing, reimbursement, and manufacturing of pharmaceutical products Review of Administration telehealth policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RIDDELL SPORTS, INC. via POLSINELLI PC
2021 · second_quarter · Q2
Issues pertaining to the use of consumer sporting goods Review of Administration COVID policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEARING INDUSTRIES ASSOCIATION via POLSINELLI PC
2021 · second_quarter · Q2
Issues pertaining to the coverage of hearing aid devices.
Issues pertaining to the regulation of hearing aids and over-the-counter hearing aid devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Q1
Issues related to the coverage and reimbursement of cancer therapies and diagnostic products.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HAPPIEST BABY, INC. via POLSINELLI PC
2021 · first_quarter · Q1
Issues pertaining to the use of products by health care providers and consumers
Issues pertaining to the use of products by health care providers and consumers
Issues pertaining to the use of products by health care providers and consumers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GT MEDICAL TECHNOLOGIES, INC. via POLSINELLI PC
2021 · first_quarter · Q1
Issues pertaining to Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROCEPT BIOROBOTICS via POLSINELLI PC
2021 · first_quarter · Q1
Issues pertaining to Medicare coverage of medical devices
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · first_quarter · Q1
Issues pertaining to patient access to cancer therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Q1
Issues related to patient safety and quality
Issues related to the implementation of the Drug Quality & Security Act (Public Law 113-54) HR 7518 The Safer Compounding in Hospitals Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Q1
Issues related to radiation oncology treatment Issues pertaining to the Radiation Oncology Alternative Payment Model
Issues related to increased access to radiation oncology therapies
Issues related to oncology treatment products and services
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEARING INDUSTRIES ASSOCIATION via POLSINELLI PC
2021 · first_quarter · Q1
Issues pertaining to the regulation of hearing aids and over-the-counter hearing aid devices
Issues pertaining to the coverage of hearing aid devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TEVA PHARMACEUTICALS USA, INC. via POLSINELLI PC
2021 · first_quarter · Q1
H.R.1319, American Rescue Plan Act Issues related to pricing, reimbursement, and manufacturing of pharmaceutical products Review of Administration telehealth policies
H.R.1319, American Rescue Plan Act Issues related to pricing, reimbursement, and manufacturing of pharmaceutical products Review of Administration telehealth policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RIDDELL SPORTS, INC. via POLSINELLI PC
2021 · first_quarter · Q1
H.R.1319, American Rescue Plan Act FTC Reauthorization Act of 2021 (Not introduced) Review of Administration COVID policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TEVA PHARMACEUTICALS USA, INC. via POLSINELLI PC
2020 · fourth_quarter · Q4
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 133, FY2021 Omnibus and COVID Relief and Response Act Review of Administration drug pricing and telehealth policies
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 133, FY2021 Omnibus and COVID Relief and Response Act Review of Administration drug pricing and telehealth policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RIDDELL SPORTS, INC. via POLSINELLI PC
2020 · fourth_quarter · Q4
H.R. 280, Concussion Awareness and Education Act FTC Reauthorization Act of 2020 (Not introduced) H.R. 133, FY2021 Omnibus and COVID Relief and Response Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Q4
Issues related to the coverage and reimbursement of cancer therapies and diagnostic products.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HAPPIEST BABY, INC. via POLSINELLI PC
2020 · fourth_quarter · Q4
Issues pertaining to the use of products by health care providers and consumers
Issues pertaining to the use of products by health care providers and consumers
Issues pertaining to the use of products by health care providers and consumers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GT MEDICAL TECHNOLOGIES, INC. via POLSINELLI PC
2020 · fourth_quarter · Q4
Issues pertaining to Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROCEPT BIOROBOTICS via POLSINELLI PC
2020 · fourth_quarter · Q4
Issues pertaining to Medicare coverage of medical devices
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Q4
Issues pertaining to patient access to cancer therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Q4
Issues related to the implementation of the Drug Quality & Security Act (Public Law 113-54) HR 7518 The Safer Compounding in Hospitals Act
Issues related to patient safety and quality
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Q4
Issues related to oncology treatment products and services
Issues related to increased access to radiation oncology therapies
Issues related to radiation oncology treatment Issues pertaining to the Radiation Oncology Alternative Payment Model
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEARING INDUSTRIES ASSOCIATION via POLSINELLI PC
2020 · fourth_quarter · Q4
Issues pertaining to the regulation of hearing aids and over-the-counter hearing aid devices.
Issues pertaining to the coverage of hearing aid devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Q3
Issues related to the coverage and reimbursement of cancer therapies and diagnostic products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · RR
Issues related to the coverage and reimbursement of cancer therapies and diagnostic products.
HAPPIEST BABY, INC. via POLSINELLI PC
2020 · third_quarter · Q3
Issues pertaining to the use of products by health care providers and consumers
Issues pertaining to the use of products by health care providers and consumers
Issues pertaining to the use of products by health care providers and consumers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GT MEDICAL TECHNOLOGIES, INC. via POLSINELLI PC
2020 · third_quarter · Q3
Issues pertaining to Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROCEPT BIOROBOTICS via POLSINELLI PC
2020 · third_quarter · Q3
Issues pertaining to Medicare coverage of medical devices
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Q3
Issues pertaining to patient access to cancer therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Q3
Issues related to patient safety and quality
Issues related to the implementation of the Drug Quality & Security Act (Public Law 113-54)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Q3
Issues related to radiation oncology treatment Issues pertaining to the Radiation Oncology Alternative Payment Model
Issues related to increased access to radiation oncology therapies
Issues related to oncology treatment products and services
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TEVA PHARMACEUTICALS USA, INC. via POLSINELLI PC
2020 · third_quarter · Q3
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing and telehealth policies H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing and telehealth policies H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RIDDELL SPORTS, INC. via POLSINELLI PC
2020 · third_quarter · Q3
H.R. 280, Concussion Awareness and Education Act FTC Reauthorization Act of 2020 (Not introduced) Coronavirus stimulus legislation H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEARING INDUSTRIES ASSOCIATION via POLSINELLI PC
2020 · third_quarter · Q3
Issues pertaining to the coverage of hearing aid devices.
Issues pertaining to the regulation of hearing aids and over-the-counter hearing aid devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVANOS MEDICAL, INC. (FKA HALYARD HEALTH, INC.) via POLSINELLI PC
2020 · third_quarter · Q3
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GT MEDICAL TECHNOLOGIES, INC. via POLSINELLI PC
2020 · second_quarter · Q2
Issues pertaining to Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROCEPT BIOROBOTICS via POLSINELLI PC
2020 · second_quarter · Q2
Issues pertaining to Medicare coverage of medical devices
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · second_quarter · Q2
Issues pertaining to patient access to cancer therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Q2
Issues related to patient safety and quality
Issues related to the implementation of the Drug Quality & Security Act (Public Law 113-54)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Q2
Issues related to radiation oncology treatment Issues pertaining to the Radiation Oncology Alternative Payment Model
Issues related to oncology treatment products and services
Issues related to increased access to radiation oncology therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HAPPIEST BABY, INC. via POLSINELLI PC
2020 · second_quarter · Q2
Issues pertaining to the use of products by health care providers and consumers
Issues pertaining to the use of products by health care providers and consumers
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
AVANOS MEDICAL, INC. (FKA HALYARD HEALTH, INC.) via POLSINELLI PC
2020 · second_quarter · Q2
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
TEVA PHARMACEUTICALS USA, INC. via POLSINELLI PC
2020 · second_quarter · Q2
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing policies
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HAPPIEST BABY, INC. via POLSINELLI PC
2020 · second_quarter · RR
Issues pertaining to the use of products by health care providers and consumers
Issues pertaining to the use of products by health care providers and consumers
HEARING INDUSTRIES ASSOCIATION via POLSINELLI PC
2020 · second_quarter · Q2
Issues pertaining to the regulation of hearing aids and over-the-counter hearing aid devices.
Issues pertaining to the coverage of hearing aid devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GT MEDICAL TECHNOLOGIES, INC. via POLSINELLI PC
2020 · first_quarter · Q1
Issues pertaining to Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROCEPT BIOROBOTICS via POLSINELLI PC
2020 · first_quarter · Q1
Issues pertaining to Medicare coverage of medical devices
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Q1
Issues pertaining to patient access to cancer therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Q1
Issues related to patient safety and quality
Issues related to the implementation of the Drug Quality & Security Act (Public Law 113-54)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Q1
Issues related to radiation oncology treatment Issues pertaining to the Radiation Oncology Alternative Payment Model
Issues related to increased access to radiation oncology therapies
Issues related to oncology treatment products and services
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GT MEDICAL TECHNOLOGIES, INC. via POLSINELLI PC
2020 · first_quarter · RR
Issues pertaining to Medicare reimbursement
TEVA PHARMACEUTICALS USA, INC. via POLSINELLI PC
2020 · first_quarter · Q1
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, Families First Coronavirus Response Act H.R. 748, CARES Act Review of Administration drug pricing policies
S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, Families First Coronavirus Response Act H.R. 748, CARES Act Review of Administration drug pricing policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE